Sivextro (tedizolid) / Merck (MSD), Nabriva Therap 
Welcome,         Profile    Billing    Logout  

9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sivextro (tedizolid) / Merck (MSD), Nabriva Therap
2018-002465-18: Efficacy and tolerance of 4 weeks of tedizolid in prosthetic joint infections treated with implant removal Eficacia y tolerancia de 4 semanas de tedizolid en infecciones articulares protésicas tratadas previamente con recambio del implante

Not yet recruiting
4
20
Europe
Tablet, SIVEXTRO
Fundació Clínic per a la Recerca Biomèdica, Bristol-Myers Squid
prosthetic joint infections treated with implant removal. infecciones de prótesis articulares tratadas con recambio de implante., Prosthetic joint infections treated with implant removal. Infecciones de prótesis articulares tratadas con recambio de implante., Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
2020-001024-34: Oral antimicrobial treatment vs. outpatient parenteral for infectiveendocarditis. Tratamiento antimicrobiano oral vs. parenteral ambulatorio para la endocarditis infecciosa

Not yet recruiting
4
360
Europe
amoxicillin, cefaclor, ciprofloxacin, clindamycin, Dicloxacillin, Fusidic acid, Fusidic Acid, Levofloxacin, levofloxacin, Linezolid, Moxifloxacin, Rifampicin, Sulfamethoxazole/trimethoprim, sulfamethoxazole /trimethoprin, Tedizolid, cefaclor, Dicloxacillin, Dicloxaxillin ev, Rifampicina, septrin, 49708-146-01, 856866-72-3, Tablet, Injection, Solution for injection, Solution for infusion, Capsule, Concentrate for solution for injection/infusion, , Film-coated tablet, Coated tablet, Solution for solution for infusion, Concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Concentrate and solvent for concentrate for solution for infusion, Amoxicillin, ciprofloxacin
Fundació Clínic per a la Recerca Biomèdica, Instituto de Salud Carlos III
infective endocarditis endocarditis infecciosa, infective endocarditis endocarditis infecciosa, Diseases [C] - Cardiovascular Diseases [C14]
 
 
OraPAT-IEGAMES, NCT05398679: Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis

Not yet recruiting
4
360
Europe
Cefaclor, Ciprofloxacin Tablets, Ciprofloxacin Injection, Clindamycin Oral Capsule, Clindamycin Injection, Dicloxacillin Oral Capsule, Dicloxacillin, Fusidic Acid Only Product in Oral Dose Form, Fusidic Acid Only Product in Parenteral Dose Form, Levofloxacin Oral Tablet, Levofloxacin Injection, Linezolid Oral Tablet, Linezolid Injectable Product, Moxifloxacin tablet, Moxifloxacin Injectable Product, Rifampicin Only Product in Oral Dose Form, Rifampicin Only Product in Parenteral Dose Form, Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim], Sulfamethoxazole / Trimethoprim Injectable Product, Tedizolid Oral Tablet, Tedizolid Injection, Amoxicillin Capsules, Amoxicillin, Cefaclor Capsules
Fundacion Clinic per a la Recerca Biomédica
Endocarditis Infective
06/24
12/24
ABSSSI, NCT03176134 / 2016-003884-20: A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

Completed
3
100
Europe, US, RoW
Tedizolid phosphate, MK-1986, TR-701 FA, Comparator
Merck Sharp & Dohme LLC
Acute Bacterial Skin and Skin Structure Infections
07/23
07/23
NCT03009045: Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)

Completed
2
44
US
Tedizolid, tedizolid phosphate, Sivextro
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Bone and Joint Infection
03/21
08/21
TEDITUB, NCT05534750: Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis

Recruiting
2
60
Europe
Tedizolid arm (SIVEXTRO®), Linezolid arm (ZYVOXID®), Standard quadruple therapy arm
Assistance Publique - Hôpitaux de Paris
Tuberculosis, Multidrug Resistant Tuberculosis
04/25
05/25
MK-1986-014, NCT03217565 / 2017-000953-38: A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections

Completed
1
47
Europe, US, RoW
IV Tedizolid Phosphate, Oral Suspension Tedizolid Phosphate
Merck Sharp & Dohme LLC
Gram-Positive Infections
03/23
03/23
MK-1986-044, NCT06609161: A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults

Completed
1
18
US
Tedizolid Phosphate Oral Formulation 1 (Reference), Tedizolid Phosphate Oral Formulation 2 (Test)
Merck Sharp & Dohme LLC
Healthy
08/24
08/24
NEW_SAFE, NCT03941951: Study to Optimize the Use of New Antibiotics

Recruiting
N/A
900
Europe
Non-impositive Program for Optimizing the Use of Antimicrobials
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Bacterial Infections, Fungal Infection
12/20
12/22

Download Options